Buserelin
From Wikipedia, the free encyclopedia
Buserelin
|
|
Systematic (IUPAC) name | |
? | |
Identifiers | |
CAS number | |
ATC code | L02 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C62H90N16O15 |
Mol. mass | 1299.48 g/mol |
Synonyms | D-Ser(Tbu)6EA10LHRH |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | 72 to 80 minutes |
Excretion | Renal |
Therapeutic considerations | |
Pregnancy cat. |
X |
Legal status |
℞-only |
Routes | implant, intranasal |
Buserelin is a Gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
It is normally delivered via a nasal spray but is also available as an injection.
Buserelin acetate is marketed by Sanofi-Aventis under the brand name Suprefact.